Padeliporfin assigned FDA Orphan Drug Designation for upper tract urothelial cancer

The FDA has granted approval for the Phase 3 clinical trial of Padeliporfin ImPACT in patients with low-grade upper tract urothelial cancer (UTUC), and Fast Track designation for the treatment of adult patients with low-grade and unifocal high-grade UTUC.

Source:

Biospace Inc.